<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795128</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI322A103</org_study_id>
    <nct_id>NCT04795128</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy</brief_title>
  <official_title>A Phase I Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study evaluating the safety, tolerability and preliminary efficacy of&#xD;
      IBI322 in hematologic malignancy subjects who failed standard treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1a/1b study will be conducted to evaluate the tolerability, safety, PK, PD,&#xD;
      immunogenicity and preliminary antitumor activity of IBI322 in China. Phase 1a is dose&#xD;
      escalation and plans to enroll approximately 39-102 subjects with hematologic malignancy who&#xD;
      failed the standard treatment. Phase 1b is dose expansion, and plans to enroll approximately&#xD;
      80 subjects with hematologic malignancy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">November 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment related AEs</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
    <description>safety</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with response</measure>
    <time_frame>Last patient enrolled+24 weeks</time_frame>
    <description>preliminary efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters: The area under the curve (AUC)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
    <description>safety and preliminary efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: Maximum concentration (Cmax)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
    <description>safety and preliminary efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: The half-life (t1/2)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: Clearance(CL)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: Volume of distribution (V)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of ADA and Nab</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
    <description>safety and preliminary efficacy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>IBI322</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI322</intervention_name>
    <description>Recombinant anti-human CD47/PD-L1 bispecific antibody injection</description>
    <arm_group_label>IBI322</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically/cytology confirmed, hematologic malignancy who failed the standard&#xD;
             treatment.&#xD;
&#xD;
          2. At least one evaluable lesion.&#xD;
&#xD;
          3. Male or female subject above 18 years old, no more than 75 years old.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) performance status 0 ~&#xD;
             2.&#xD;
&#xD;
          5. Must have adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to any anti-CD47 monoclonal antibody, SIRPα antibody, or CD47/SIRPα&#xD;
             recombinant protein.&#xD;
&#xD;
          2. Previous exposure to chimeric antigen receptor T cell immunotherapy (CAR-T)&#xD;
&#xD;
          3. Subjects participating in another interventional clinical study, except for:&#xD;
             observational (non-interventional) clinical studies or survival follow-up phase of&#xD;
             interventional studies.&#xD;
&#xD;
          4. Subjects who are used of anticoagulants and/or aspirin or other non-steroidal&#xD;
             anti-inflammatory drugs within 2 weeks prior to the study&#xD;
&#xD;
          5. Subjects who have a history of blood transfusion within 2 weeks prior to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WenBin Qian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Luo</last_name>
    <phone>0512-69566088</phone>
    <email>min.luo@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School OF Medicine</name>
      <address>
        <city>Zhejiang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WenBin Qian</last_name>
      <phone>86-0571-89713674</phone>
      <email>qianwenb@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

